Expert Interview
A Second Look: Discussing the recent AACR 2025 data on GSK’s checkpoint blocker Jemperli in biomarker-driven rectal cancer
Ticker(s): GSKInstitution: Mayo Clinic
- Oncologist at the Mayo Clinic with special interest in neuroendocrine tumors and gastrointestinal malignancies.
- Currently manages patients with colon cancer, esophageal cancer, gallbladder cancer, liver cancer, neuroendocrine tumors, pancreatic cancer, rectal cancer, small bowel cancer, stomach cancer.
- Active in research that focuses on investigating novel treatments including targeted therapies, immunotherapy, and other agents for neuroendocrine and gastrointestinal cancers.
If you had to rate your level of excitement on a 1 to 10 scale for dostarlimab what would it be and why?
Added By: sara_adminHow do you think this study will affect the treatment landscape for dMMR patients?
Added By: sara_adminRoughly how many patients do you treat for MMRd cancers and how many are treated with immunotherapy? Is immunotherapy often combined with surgery, radiation, or chemotherapy for these patients?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
